NCT07236814

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 384 (estimated)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.

Conditions

• Influenza

Interventions

Type	Name	Description
DRUG	Suraxavir marboxil	Suraxavir marboxil (40mg on the first day)
DRUG	Oseltamivir Placebo	Oseltamivir placebo(75mg each day during the first five days)
DRUG	Oseltamivir	Oseltamivir (75mg each day during the first five days)
DRUG	Suraxavir marboxil placebo	Suraxavir marboxil placebo (40mg on the first day).

Timeline

• Start date: 2025-11-28
• Primary completion: 2027-03-01
• Completion: 2027-03-06
• First posted: 2025-11-19
• Last updated: 2026-03-23

Locations

2 sites across 1 country: China